EPCAM and melanoma: This in vivo efficacy is exclusively due to CD3 and EpCAM engagement since the Fc has been engineered to be functionally silent.(20) Furthermore, although this molecule elicited relatively low levels of T cell activation in vitro, this did not appear to be predictive of the characteristics required for in vivo efficacy in a murine melanoma model.